Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies

@article{Zuddas2011SecondGA,
  title={Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: A review of the randomized controlled studies},
  author={A. Zuddas and R. Zanni and T. Usala},
  journal={European Neuropsychopharmacology},
  year={2011},
  volume={21},
  pages={600-620}
}
In children and adolescents the Second Generation Antipsychotics (SGAs) represent the class of psychotropic drugs whose use has grown more significantly in recent years: they are primarily used for treatment of patients with disruptive behavior disorders, mood disorders and pervasive developmental disorders or mental retardation. In order to compare the efficacy and tolerability of antipsychotics against placebo or each other, a systematic Medline/PubMed search for randomized, double blind… Expand
Antipsychotics in pediatric and adolescent patients: a review of comparative safety data.
TLDR
A comparative review of the safety data available for antipsychotic drug use in pediatric populations finds quetiapine and ziprasidone display a better tolerability profile than risperidone and olanzapine, while aripiprazole seems to be the most weight-neutral. Expand
Antipsychotics in pediatric and adolescent patients: a review of comparative safety data.
TLDR
A comparative review of the safety data available for antipsychotic drug use in pediatric populations finds quetiapine and ziprasidone display a better tolerability profile than risperidone and olanzapine in terms of weight gain, glucose metabolism, increases in prolactin levels, and EPS, while aripiprazole seems to be the most weight-neutral. Expand
Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients.
TLDR
Olanzapine, quetiapines, and risperidone increase body weight but have different cardiometabolic side effect profiles and different temporal side effect patterns. Expand
Second generation antipsychotics in Asperger's Disorder and high functioning autism: a systematic review of the literature and effectiveness of meta-analysis.
TLDR
There is a lack of robustly conducted trials on the use of SGAs in the management of AD and HFA, so clinicians are cautioned to approach pharmacological treatment prudently balancing benefit with potential cardiometabolic risk. Expand
Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: design of a follow-up protocol and baseline results.
TLDR
The results show that, in the childhood-adolescent population, the presence of secondary effects begins to be observed from the first dose of the antipsychotic drug. Expand
Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents
  • E. Kirino
  • Medicine
  • Adolescent health, medicine and therapeutics
  • 2014
TLDR
Aripiprazole cannot yet be considered a preferred treatment for children and adolescents with bipolar disorder, as there is not yet evidence that aripIPrazole shows greater efficacy compared to other second-generation antipsychotics. Expand
Secondary effects of antipsychotic treatment in naive or quasi-naive children and adolescents: design of a follow-up protocol and baseline results.
TLDR
These results show that, in the childhood–adolescent population, the presence of secondary effects begins to be observed from the first dose of the antipsychotic drug. Expand
Absence of Change in Corrected QT Interval in Children and Adolescents Receiving Antipsychotic Treatment: A 12 Month Study.
TLDR
In this sample of treatment-naïve children and adolescents receiving AP treatment, SGA seem to have a safe heart side effect profile in the child and adolescent population. Expand
A Naturalistic Comparison of Methylphenidate and Risperidone Monotherapy in Drug-Naive Youth With Attention-Deficit/Hyperactivity Disorder Comorbid With Oppositional Defiant Disorder and Aggression
TLDR
The findings suggest that when ADHD is comorbid with ODD and aggression MPH and risperidone are both effective on aggressive behavior, but only stimulants are effective on ADHD symptoms. Expand
Safety and Pharmacokinetics of Atypical Antipsychotics in Children and Adolescents
TLDR
Current evidence indicates that sedation, hyperprolactinemia, and metabolic abnormalities such as excess weight gain, diabetes, and related cardiovascular effects were clinically relevant adverse effects in young patients, with the individual agents differing in their propensity to induce these effects. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 140 REFERENCES
Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: Comprehensive review of prospective head-to-head and placebo-controlled comparisons
TLDR
SGAs do not behave as a homogeneous group in children and adolescents with psychotic and mood disorders, and the heterogeneity within the SGA group is mainly due to differences in the rates and severity of adverse events, especially regarding weight gain as a proxy for the risk of cardiometabolic disturbances. Expand
Efficacy and Tolerability of Second-Generation Antipsychotics in Children and Adolescents With Schizophrenia
TLDR
Preliminary data suggest that SGA use can lead to the development of diabetes in some youth, a disease which itself carries with it significant morbidity and mortality, and the urgent need to develop therapeutic strategies to prevent and/or mitigate weight gain and diabetes early in the course of treatment in this population. Expand
Antipsychotics in children and adolescents: Increasing use, evidence for efficacy and safety concerns
TLDR
An expert panel to review relevant efficacy and safety data, and identify needs for further research, concluded that research is also needed to understand the mechanisms underlying antipsychotic-induced toxicities in order to develop effective preventive and treatment strategies. Expand
Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes.
  • C. Correll
  • Medicine
  • Journal of the American Academy of Child and Adolescent Psychiatry
  • 2008
TLDR
The present article aims to succinctly review available data on antipsychotic-related adverse effects in children and adolescents and provide a practical guide for the evaluation and management of antipsychotics-related effects in this vulnerable population. Expand
Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: a double-blind, placebo-controlled pilot trial.
Risperidone, an antipsychotic agent with combined serotonin (5-HT2A) and dopamine (D2) receptor-blocking properties, is associated with fewer extrapyramidal side effects in adults than conventionalExpand
Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics.
TLDR
Metabolic and hormonal side effects of SGAs in children and adolescents should be carefully monitored when prescribing these drugs. Expand
Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.
TLDR
At daily doses of 0.5-2.5 mg and 3-6 mg, risperidone was effective and well tolerated in children and adolescents experiencing acute manic or mixed episodes of bipolar I disorder. Expand
A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder.
TLDR
Olanzapine may be a promising treatment for improving global functioning of PDDs, but the risk of significant weight gain remains a concern. Expand
Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.
TLDR
While not demonstrating definitively the superiority of clozapine compared with olanzapine in treatment-refractory childhood-onset schizophrenia, the study suggests that clozamine has a more favorable profile of clinical response, which is balanced against more associated adverse events. Expand
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
TLDR
Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults and well tolerated, with no evidence of extrapyramidal effects, cardiac events, or seizures. Expand
...
1
2
3
4
5
...